SCHEMBL16640905

SCHEMBL16640905

CC(C)CC1(C)NC(=O)N(CC2CCN(C(=O)NC(C)C)CC2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.38
ALDH1A1 P00352 4/20 0.38
CYP1A2 P05177 2/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PKM P14618 1/20 0.35
MDM4 O15151 1/20 0.34
MDM2 Q00987 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
CYP2C9 P11712 1/20 0.34
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7521825 0.90 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1CYP1A2POLB
SCHEMBL16640907 0.82 CNR2 (0.46) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL7529097 0.79 HSD11B1 (0.41) SMN1; SMN2LMNAALDH1A1POLBGAA
SCHEMBL16644950 0.79 HRH3 (0.48)
SCHEMBL7524948 0.79 HSD11B1 (0.42) LMNAALDH1A1POLBKMT2AGAA
SCHEMBL7529195 0.78 LMNA (0.38) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL7524008 0.78 POLB (0.40) SMN1; SMN2LMNAALDH1A1POLBKMT2A
SCHEMBL7520536 0.76 KMT2A (0.36) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL7529054 0.76 HTT (0.37) SMN1; SMN2POLBKMT2AGAAL3MBTL1
SCHEMBL7521703 0.76 SMN1; SMN2 (0.34) SMN1; SMN2LMNAALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9416108-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-9416108-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 US disclosed
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PRSS1, BCHE, CTSZ SMN1; SMN2 1186/4885LMNA 2376/4885ALDH1A1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.